In firecracker, it states:
"In the case of both chronic renal failure and malabsorption syndrome, the treatment of secondary hyperparathyroidism includes calcitriol (active vitamin D) and phosphate binders (aluminum hydroxide or calcium carbonate). Elevated serum phosphate levels directly depress serum calcium levels, and phosphate binders are used to decrease the prevailing hyperphosphatemia."
Phosphate binders make pharmacologic sense in hyperparathyroidism due to chronic renal failure, due to the fact that there is hyperphosphatemia. However, I thought secondary hyperparathyroidism due to malabsorption syndrome is characterized by hypophosphatemia. Is this correct? If it is correct, then why would you use phosphate binders in the context of hyperparathyroidism due to malabsorption syndrome?
"In the case of both chronic renal failure and malabsorption syndrome, the treatment of secondary hyperparathyroidism includes calcitriol (active vitamin D) and phosphate binders (aluminum hydroxide or calcium carbonate). Elevated serum phosphate levels directly depress serum calcium levels, and phosphate binders are used to decrease the prevailing hyperphosphatemia."
Phosphate binders make pharmacologic sense in hyperparathyroidism due to chronic renal failure, due to the fact that there is hyperphosphatemia. However, I thought secondary hyperparathyroidism due to malabsorption syndrome is characterized by hypophosphatemia. Is this correct? If it is correct, then why would you use phosphate binders in the context of hyperparathyroidism due to malabsorption syndrome?
Last edited: